Sign up for periodic reports and bulletins
FREE access; FREE of commercials; FREE to use
Posted October 29, 2016: by Bill Sardi
The movement toward recreational and not just medical marijuana use at the State level is inevitably going to change the fabric of America.
There were lines of hundreds of people outside pot shops in Colorado when just one herbal product was legalized there in 2012. In my years in the natural health industry there have been swells of public interest over DMSO, coral calcium, Echinacea, resveratrol, even vitamin C with the publication of Linus Pauling’s book VITAMIN C AND THE COMMON COLD (which by the way resulted in a 300% in mortality from coronary heart disease). But there have never been lines of customers waiting to buy any dietary supplement as there has been for a single herb — recreational marijuana.
Posted July 7, 2016: by Bill Sardi
According to one source, online sales of dietary supplements now represents 15.5% of overall sales and is a fast growing channel. [McKinsey Marketing] But that may not be for long. Consider these recent events privately reported to me.
A dietary supplement company that had been doing business for over a decade online was in the middle of a December 2015 year-end sale when it ran out of product. With the consent of consumers who wanted year-end pricing, orders were taken but not processed and a promise to ship in mid January 2016 was offered.
Posted May 17, 2016: by Bill Sardi
Most of the people on planet earth live on less than $4 a day. Many are illiterate. In their struggle to survive, they cannot even fathom what is going on in the elitist genetic laboratories around the world where the quest to develop a genetically perfect human is now on the drawing board.
Yes, a synthetic human if you will. Geneticists have already read the human genome but now they want to re-write it. That is, synthetic genetic information, the entire library of genes called the human genome, would be implanted inside a living cell in the first step toward creating a human being without a biological father or mother.
Posted April 21, 2016: by Bill Sardi
Rates of obesity and diabetes rose in an era of endless diet books, calorie counting and low-fat diets. Something was obviously amiss. Arteries still become atherosclerotic on the 5-A-Day Plant Food Diet Promoted By Public Health Authorities. In contrast, people in Japan are leaner and healthier and live longer without local gyms and myriads of medications or even dietary advice. France has the most centenarians per capita and eats a diet rich in fats and cholesterol.
In a complete denunciation of modern medicine, the profit-making schemes of health plans and political efforts to make healthcare available to all come to an abrupt halt with a policy-bending report published in the Journal of the American Medical Association that shows access to healthcare does not deliver health. It does deliver treatment.
Posted April 15, 2016: by Bill Sardi
“What’s up doc?” – Bugs Bunny with a carrot in his mouth
Move over Bugs Bunny. Your beta carotene-rich carrots which converts to vitamin A in the liver to eventually form rhodopsin, the visual chemical of sight at the back of the eyes, is about to get bumped to second place by a cup of java.
So far, cataract surgeons, as effective as they are at restoring sight these days with lens implants (even multi-focal intraocular lenses) with 95+% success, have been able to deny eye drops for cataracts are effective at delaying or totally preventing cataracts.
Posted April 11, 2016: by Bill Sardi
Despite its unconvincing history and its blunt but cursory dismissal by modern medicine, vitamin C therapy for cancer may (finally) be undergoing an unexpected resurgence and it isn’t being led by a bunch of naturopaths and vitamin wackos.
Scientific investigators from 13 different countries operating at 28 universities and established clinics have published 37 papers in the past four years on the need to produce more evidence of vitamin C’s safety and efficacy for cancer treatment. In other words, vitamin C therapy is not dead and buried 37 years after it was first introduced by Nobel Laureate Linus Pauling and Scottish physician Ewan Cameron.
Posted April 8, 2016: by Bill Sardi
A modern reanalysis reveals there are ways to optimize vitamin C therapy and significantly prolong the lives of cancer patients.
In 1978 Dr. Ewan Cameron and Nobel Laureate Linus Pauling published a study that reported long-term survival of cancer patients who had undergone intravenous + oral mega-dose (10,000 milligrams) vitamin C therapy. Vitamin C-treated cancer patients lived 20 times longer than a control group. While most patients succumbed to their cancer, intravenous vitamin C therapy outperformed conventional cancer therapy. By comparison, 0.4% of cancer patients who did not undergo vitamin C therapy survived 1-year versus 22% who had undergone intravenous vitamin C therapy. [Proceedings National Academy Science 1978]
Posted March 7, 2016: by Bill Sardi
Labeled as “health fanatics” and “vitamin whackos,” the users of mega-dose vitamin C pills are about to be vindicated. No more hiding their vitamin C pills from their doctors. No more condescending glances from their friends when they say they are taking a few grams of vitamin C every day. According to newly revealed science, the belittled mega-dose vitamin C users may be purchasing the cheapest and most effective health insurance one can buy.
The prevalent belief is that vitamin C is an essential nutrient but excessive amounts consumed from mega-dose vitamin pills produce expensive urine since excesses are excreted. This flawed idea emanates from studies conducted by researchers at the National Institutes of Health (NIH) in 1996. [Proceedings Natl. Academy Science 93:14344-8, 1996] Ever since then physicians, pharmacists, dietitians and other health practitioners have echoed the same mistaken chorus — you’re wasting your money by taking mega-dose vitamin C pills.
Posted February 5, 2016: by Bill Sardi
The U.S. Food & Drug Administration (FDA) is loath to monitor the safety of drugs following their initial approval. More than a decade after shortcomings within the U.S. Food & Drug Administration in conducting follow-up safety studies after new drugs are approved were identified, the General Accounting Office (GAO) says the FDA is still dragging its feet by utilizing technology that requires manual entry of data.
In January of 2016 the General Accounting Office (GAO) of the U.S. finally got around to find out why it has taken the Food & Drug Administration so long to require drug companies to publish all of their follow-up safety data once their drugs gain regulatory approval.
In an era when the FDA is conceding to pressure to approve new drugs more rapidly, it is not properly monitoring safety of these drugs as it should, says the GAO report. The GAO found that more than half of drug sponsors’ submissions involving about 1400 post-market studies required or requested from the FDA between March 2008 and September 2013 were delayed or overdue.
Posted January 16, 2016: by Bill Sardi
I have written extensively at LewRockwell.com about cholesterol and statin drugs: A new injectable cholesterol drug (July 28, 2015); When will modern medicine give up its cholesterol cash-cow? (Dec 27, 2013); Statin cholesterol-lowering drugs work via reduction of iron (May 27, 2013); Statin drugs don’t save lives (Nov 10, 2008); Coronary calcium predicts future heart attacks, not cholesterol (March 28, 2008); Who will tell the people? It isn’t cholesterol. (Feb 5, 2007);
There have been numerous other critics of statin drugs: Don’t give more patients statins, John Abramson/Rita Redberg, NY times (Nov 13, 2013); The Great Cholesterol Con, Malcolm Kendrick (Oct 1, 2008); The Cholesterol Myths, Uffe Ravnskov (Oct 1, 2000); The Statin Damage Crisis, Duane Graveline (July 29, 2012); Lipitor Thief Of Memory, Duane Graveline (Sept 23, 2010)
Yet the American population has been systematically educated and can be considered a nation of ingrained cholesterol phobes and the statin drug industry continues to rake in billions of dollars in revenues.